Autoimmune diseases of the peripheral nervous system

Autoimmunity Reviews

Volumn 11, Issue 3, 2012, Pages 191-195

  Kieseier, Bernd C ^a   Lehmann, Helmar C ^a   Hörste, Gerd Meyer zu ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain Barr syndrome; Molecular mimicry; Monoclonal gammopathy; Multifocal motor neuropathy; Therapy

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DNA SYNTHESIS; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MACROPHAGE; PERIPHERAL NERVE; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOIMMUNITY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; PERIPHERAL NERVOUS SYSTEM; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 84855971745     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.05.011     Document Type: Review

References (35)

1. Gold R., Archelos J.J., Hartung H.P. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 1999, 9:343-360.
2. Kieseier B.C., Kiefer R., Gold R., Hemmer B., Willison H.J., Hartung H.P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004, 30:131-156.
3. Wekerle H., Schwab M., Linington C., Meyermann R. Antigen presentation in the peripheral nervous system: Schwann cells present endogenous myelin autoantigens to lymphocytes. Eur J Immunol 1986, 16:1551-1557.
4. Mäurer M., Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002, 15:617-622.
5. Griffin J.W., George R., Ho T. Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 1993, 52:553-560.
6. Kiefer R., Kieseier B.C., Stoll G., Hartung H.P. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol 2001, 64:109-127.
7. Gold R., Kieseier B.C., Hartung H.P. Immunological properties of the peripheral nervous system. In Clinical Neuroimmunology 2005, 77-86. Oxford University Press. J. Antel, G. Birnbaum, H.-P. Hartung, A. Vincent (Eds.).
8. Gold R., Archelos J.J., Hartung H.-P. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 1999, 9:343-360.
9. Kaufmann S.H., Schaible U.E. Antigen presentation and recognition in bacterial infections. Curr Opin Immunol 2005, 17:79-87.
10. De Libero G., Mori L. Recognition of lipid antigens by T cells. Nat Rev Immunol 2005, 5:485-496.
11. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
12. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis 2001, 1:29-37.
13. Willison H.J. The immunobiology of Guillain-Barre syndromes. J Peripher Nerv Syst 2005, 10:94-112.
14. Dalakas M.C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol 1999, 12:403-409.
15. Hartung H.-P., Hughes R.A.C., Taylor W.A. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990, 40:215-218.
16. Hartung H.-P., Reiners K., Schmidt B., Stoll G., Toyka K.V. Serum interleukin-2 concentrations in the Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991, 30:48-53.
17. Csurhes P.A., Sullivan A.A., Green K., Pender M.P., McCombe P.A. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005, 76:1431-1439.
18. Caporale C.M., Papola F., Fioroni M.A., Aureli A., Giovannini A., Notturno F., et al. Susceptibility to Guillain-Barre syndrome is associated to polymorphisms of CD1 genes. J Neuroimmunol 2006.
19. Csurhes P.A., Sullivan A.A., Green K., Greer J.M., Pender M.P., McCombe P.A. Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barre syndrome. J Clin Neurosci 2005, 12:409-415.
20. Koller H., Kieseier B.C., Jander S., Hartung H.P. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343-1356.
21. Bosboom W.M., Van den Berg L.H., Mollee I., Sasker L.D., Jansen J., Wokke J.H., et al. Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy. Neurology 2001, 56:74-81.
22. Illes Z., Kondo T., Newcombe J., Oka N., Tabira T., Yamamura T. Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000, 164:4375-4381.
23. Schmidt B., Toyka K.V., Kiefer R., Full J., Hartung H.-P., Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996, 19:474-487.
24. Winer J., Hughes S., Cooper J., Ben-Smith A., Savage C. gammadelta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy. J Neurol 2002, 249:616-621.
25. Illes Z., Shimamura M., Newcombe J., Oka N., Yamamura T. Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. Int Immunol 2004, 16:223-230.
26. Previtali S.C., Feltri M.L., Archelos J.J., Quattrini A., Wrabetz L., Hartung H. Role of integrins in the peripheral nervous system. Prog Neurobiol 2001, 64:35-49.
27. Previtali S.C., Archelos J.J., Hartung H.P. Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome. Ann Neurol 1998, 44:611-621.
28. Kieseier B.C., Tani M., Mahad D., Oka N., Ho T., Woodroofe N., et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 2002, 125:823-834.
29. Koller H., Schroeter M., Kieseier B.C., Hartung H.P. Chronic inflammatory demyelinating polyneuropathy-update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol 2005, 18:273-278.
30. Nobile-Orazio E. Treatment of dys-immune neuropathies. J Neurol 2005, 252:385-395.
31. Jann S., Beretta S., Bramerio M.A. Different types of chronic inflammatory demyelinating polyneuropathy have a different clinical course and response to treatment. Muscle Nerve 2005, 32:351-356.
32. van Schaik I.N., Eftimov F., van Doorn P.A., Brusse E., van den Berg L.H., van der Pol W.L., et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010, 9:245-245.
33. Leger J.M., Behin A. Multifocal motor neuropathy. Curr Opin Neurol 2005, 18:567-573.
34. Kieseier B.C., Wiendl H., Hartung H.P. The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006, 19:433-436.
35. Wolf C., Menge T., Stenner M.P., Meyer zu Hörste G., Saleh A., Hartung H.P., et al. Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2010, 67:881-883.